{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:36:29Z","timestamp":1793824589996,"version":"4.6.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41434-024-00503-8","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T03:18:38Z","timestamp":1732677518000},"page":"301-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis"],"prefix":"10.1038","volume":"32","author":[{"given":"Bunchai","family":"Chongmelaxme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-532X","authenticated-orcid":false,"given":"Varalee","family":"Yodsurang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponlawat","family":"Vichayachaipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanate","family":"Srimatimanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-0387","authenticated-orcid":false,"given":"Oranee","family":"Sanmaneechai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"503_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"key":"503_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12:124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8","journal-title":"Orphanet J Rare Dis"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"key":"503_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl J Med. 2017;377:1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N. Engl J Med"},{"key":"503_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2009965.","journal-title":"N Engl J Med"},{"key":"503_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/medicina58020213","volume":"58","author":"KS Abbas","year":"2022","unstructured":"Abbas KS, Eltaras MM, El-Shahat NA, Abdelazeem B, Shaqfeh M, Bra\u0161i\u0107 JR. The safety and efficacy of nusinersen in the treatment of spinal muscular atrophy: a systematic review and meta-analysis of randomized controlled trials. Med (Kaunas). 2022;58:213. https:\/\/doi.org\/10.3390\/medicina58020213","journal-title":"Med (Kaunas)"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/hum.2022.161","volume":"34","author":"C Pascual-Morena","year":"2023","unstructured":"Pascual-Morena C, Cavero-Redondo I, Lucer\u00f3n-Lucas-Torres M, Mart\u00ednez-Garc\u00eda I, Rodr\u00edguez-Guti\u00e9rrez E, Mart\u00ednez-Vizca\u00edno V. Onasemnogene abeparvovec in type 1 spinal muscular atrophy: a systematic review and meta-analysis. Hum Gene Ther. 2023;34:129\u201338. https:\/\/doi.org\/10.1089\/hum.2022.161","journal-title":"Hum Gene Ther"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","volume":"5","author":"RS Finkel","year":"2021","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Lancet Child Adolesc Health. 2021;5:491\u2013500. https:\/\/doi.org\/10.1016\/S2352-4642(21)00100-0.","journal-title":"Lancet Child Adolesc Health"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"key":"503_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9.","journal-title":"Lancet Neurol"},{"key":"503_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28:1381\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","journal-title":"Nat Med"},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68:157\u201370. https:\/\/doi.org\/10.1002\/mus.27853.","journal-title":"Muscle Nerve"},{"key":"503_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Servais L, Xiong H, Zanoteli E, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21:1110\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(22)00339-8.","journal-title":"Lancet Neurol"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","journal-title":"Neuromuscul Disord"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","volume":"5","author":"J Glascock","year":"2018","unstructured":"Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5:145\u201358. https:\/\/doi.org\/10.3233\/JND-180304","journal-title":"J Neuromuscul Dis"},{"key":"503_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"503_CR17","doi-asserted-by":"publisher","unstructured":"Higgins JPTSJ, Savovic J, Page MJ, Hr\u00f3bjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods. Cochrane Database of Systematic Reviews; 2016. Issue 10 (Suppl 1). https:\/\/doi.org\/10.1002\/14651858.CD201601.","DOI":"10.1002\/14651858.CD201601"},{"key":"503_CR18","doi-asserted-by":"publisher","unstructured":"Abbas A, Hassan MA, Shaheen RS, Hussein A, Moawad M, Meshref M, et al. Safety and efficacy of unilateral focused ultrasound pallidotomy on motor complications in Parkinson\u2019s disease (PD): a systematic review and meta-analysis. Neurol Sci. 2024. https:\/\/doi.org\/10.1007\/s10072-024-07617-2.","DOI":"10.1007\/s10072-024-07617-2"},{"key":"503_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72:39 https:\/\/doi.org\/10.1186\/2049-3258-72-39","journal-title":"Arch Public Health"},{"key":"503_CR20","doi-asserted-by":"crossref","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019.","DOI":"10.1002\/9781119536604"},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"503_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi G, Crawford TO, M\u00fcller-Felber W, Shieh PB, Richardson R, Natarajan N, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. Muscle Nerve. 2021;63:668\u201377. https:\/\/doi.org\/10.1002\/mus.27187.","journal-title":"Muscle Nerve"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies. Neurology. 2019;92:e2492\u2013e506. https:\/\/doi.org\/10.1212\/WNL.0000000000007527.","journal-title":"Neurology"},{"key":"503_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000002445.","journal-title":"Neurology"},{"key":"503_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","volume":"9","author":"JM Kwon","year":"2022","unstructured":"Kwon JM, Arya K, Kuntz N, Phan HC, Sieburg C, Swoboda KJ, et al. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9:810\u20138. https:\/\/doi.org\/10.1002\/acn3.51560.","journal-title":"Ann Clin Transl Neurol"},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","volume":"77","author":"A Chacko","year":"2022","unstructured":"Chacko A, Sly PD, Ware RS, Begum N, Deegan S, Thomas N, et al. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3. Thorax. 2022;77:40\u20136. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216564","journal-title":"Thorax"},{"key":"503_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.prrv.2020.09.002","volume":"39","author":"KA Chen","year":"2021","unstructured":"Chen KA, Widger J, Teng A, Fitzgerald DA, D\u2019Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience. Paediatr Respir Rev. 2021;39:54\u201360. https:\/\/doi.org\/10.1016\/j.prrv.2020.09.002","journal-title":"Paediatr Respir Rev"},{"key":"503_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Holland S, Kariyawasam D, Herbert K, Barclay P, Cairns A, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9:339\u201350. https:\/\/doi.org\/10.1002\/acn3.51519","journal-title":"Ann Clin Transl Neurol"},{"key":"503_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.nmd.2023.04.007","volume":"33","author":"K Gonski","year":"2023","unstructured":"Gonski K, Chuang S, Teng A, Thambipillay G, Farrar MA, Menezes MP, et al. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience. Neuromuscul Disord. 2023;33:531\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2023.04.007","journal-title":"Neuromuscul Disord"},{"key":"503_CR30","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","volume":"91","author":"K Aragon-Gawinska","year":"2018","unstructured":"Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology. 2018;91:e1312\u2013e8. https:\/\/doi.org\/10.1212\/WNL.0000000000006281.","journal-title":"Neurology"},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.arcped.2023.10.009","volume":"31","author":"F Audic","year":"2024","unstructured":"Audic F, Dubois SM, Durigneux J, Barnerias C, Isapof A, Nougues MC, et al. Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type. Arch Pediatr. 2024;31:117\u201323. https:\/\/doi.org\/10.1016\/j.arcped.2023.10.009","journal-title":"Arch Pediatr"},{"key":"503_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ppul.25142","volume":"56","author":"M G\u00f3mez-Garc\u00eda de la Banda","year":"2021","unstructured":"G\u00f3mez-Garc\u00eda de la Banda M, Amaddeo A, Khirani S, Pruvost S, Barnerias C, Dabaj I, et al. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. Pediatr Pulmonol. 2021;56:299\u2013306. https:\/\/doi.org\/10.1002\/ppul.25142","journal-title":"Pediatr Pulmonol"},{"key":"503_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fped.2020.00004","volume":"8","author":"M Hully","year":"2020","unstructured":"Hully M, Barnerias C, Chabalier D, Le Guen S, Germa V, Deladriere E, et al. Palliative care in SMA type 1: a prospective multicenter french study based on parents\u2019 reports. Front Pediatr. 2020;8:4 https:\/\/doi.org\/10.3389\/fped.2020.00004.","journal-title":"Front Pediatr"},{"key":"503_CR34","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/jcm12082839","volume":"12","author":"A Belan\u010di\u0107","year":"2023","unstructured":"Belan\u010di\u0107 A, Strbad T, Ku\u010dan \u0160tigli\u0107 M, Vitezi\u0107 D. Effectiveness of nusinersen in type 1, 2 and 3 spinal muscular atrophy: croatian real-world data. J Clin Med. 2023;12:2839 https:\/\/doi.org\/10.3390\/jcm12082839","journal-title":"J Clin Med"},{"key":"503_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/jpm14030244","volume":"14","author":"A Belan\u010di\u0107","year":"2024","unstructured":"Belan\u010di\u0107 A, Strbad T, Ku\u010dan \u0160tigli\u0107 M, Vitezi\u0107 D. Switching from nusinersen to risdiplam: a Croatian real-world experience on effectiveness and safety. J Pers Med. 2024;14:244 https:\/\/doi.org\/10.3390\/jpm14030244","journal-title":"J Pers Med"},{"key":"503_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-230197","volume":"11","author":"B Sitas","year":"2024","unstructured":"Sitas B, Hancevic M, Bilic K, Bilic H, Bilic E. Risdiplam real world data - looking beyond motor neurons and motor function measures. J Neuromuscul Dis. 2024;11:75\u201384. https:\/\/doi.org\/10.3233\/JND-230197","journal-title":"J Neuromuscul Dis"},{"key":"503_CR37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/ene.15768","volume":"30","author":"M Pane","year":"2023","unstructured":"Pane M, Coratti G, Sansone VA, Messina S, Catteruccia M, Bruno C, et al. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function. Eur J Neurol. 2023;30:1755\u201363. https:\/\/doi.org\/10.1111\/ene.15768","journal-title":"Eur J Neurol"},{"key":"503_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","volume":"219","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Pirola A, Albamonte E, Pane M, Lizio A, D\u2019Amico A, et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen. J Pediatr. 2020;219:223\u20138 e4. https:\/\/doi.org\/10.1016\/j.jpeds.2019.12.047","journal-title":"J Pediatr"},{"key":"503_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1326528","volume":"15","author":"I Bitetti","year":"2024","unstructured":"Bitetti I, Manna MR, Stella R, Varone A. Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study. Front Neurol. 2024;15:1326528 https:\/\/doi.org\/10.3389\/fneur.2024.1326528","journal-title":"Front Neurol"},{"key":"503_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/00185787231182562","volume":"59","author":"M Favia","year":"2024","unstructured":"Favia M, Tarantino D, Cerbo LD, Sabia A, Campopiano R, Pani M. Onasemnogene abeparvovec: post-infusion efficacy and safety in patients with spinal muscular atrophy (SMA)-A Fondazione Policlinico Gemelli IRCCS Experience. Hosp Pharm. 2024;59:39\u201346. https:\/\/doi.org\/10.1177\/00185787231182562","journal-title":"Hosp Pharm"},{"key":"503_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","volume":"5","author":"A Pechmann","year":"2018","unstructured":"Pechmann A, Langer T, Schorling D, Stein S, Vogt S, Schara U, et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. J Neuromuscul Dis. 2018;5:135\u201343. https:\/\/doi.org\/10.3233\/JND-180315","journal-title":"J Neuromuscul Dis"},{"key":"503_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn A, G\u00fcnther R, Ludolph A, Schwartz O, Trollmann R, Weydt P, et al. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2022;17:276 https:\/\/doi.org\/10.1186\/s13023-022-02420-8","journal-title":"Orphanet J Rare Dis"},{"key":"503_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejpn.2022.06.001","volume":"39","author":"K Kotulska","year":"2022","unstructured":"Kotulska K, Chmielewski D, Mazurkiewicz-Be\u0142dzi\u0144ska M, Tomaszek K, Pierzchlewicz K, Rabczenko D, et al. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy. Eur J Paediatr Neurol. 2022;39:103\u20139. https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.001","journal-title":"Eur J Paediatr Neurol"},{"key":"503_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","volume":"55","author":"S Modrzejewska","year":"2021","unstructured":"Modrzejewska S, Kotulska K, Kopyta I, Gr\u0119dowska E, Emich-Widera E, Tomaszek K, et al. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland. Neurol Neurochir Pol. 2021;55:289\u201394. https:\/\/doi.org\/10.5603\/PJNNS.a2021.0020","journal-title":"Neurol Neurochir Pol"},{"key":"503_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02769-4","volume":"18","author":"A \u0141usakowska","year":"2023","unstructured":"\u0141usakowska A, W\u00f3jcik A, Fr\u0105czek A, Aragon-Gawi\u0144ska K, Potulska-Chromik A, Baranowski P, et al. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience. Orphanet J Rare Dis. 2023;18:230 https:\/\/doi.org\/10.1186\/s13023-023-02769-4","journal-title":"Orphanet J Rare Dis"},{"key":"503_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","volume":"27","author":"L Szabo","year":"2020","unstructured":"Szabo L, Gergely A, Jakus R, Fogarasi A, Grosz Z, Moln\u00e1r MJ, et al. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. Eur J Paediatr Neurol. 2020;27:37\u201342. https:\/\/doi.org\/10.1016\/j.ejpn.2020.05.002","journal-title":"Eur J Paediatr Neurol"},{"key":"503_CR47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","volume":"45","author":"H Iwayama","year":"2023","unstructured":"Iwayama H, Kawahara K, Takagi M, Numoto S, Azuma Y, Kurahashi H, et al. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2. Brain Dev. 2023;45:110\u20136. https:\/\/doi.org\/10.1016\/j.braindev.2022.10.006","journal-title":"Brain Dev"},{"key":"503_CR48","doi-asserted-by":"publisher","unstructured":"Tachibana Y, Sato R, Makioka H, Hoshino M, Jin M Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan. Int J Neurosci. 2023:1-13. https:\/\/doi.org\/10.1080\/00207454.2023.2251662.","DOI":"10.1080\/00207454.2023.2251662"},{"key":"503_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4103\/aian.AIAN_524_20","volume":"23","author":"AR Kim","year":"2020","unstructured":"Kim AR, Lee JM, Min YS, Lee H, Kim D, Hwang SK, et al. Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: a retrospective study. Ann Indian Acad Neurol. 2020;23:796\u2013801. https:\/\/doi.org\/10.4103\/aian.AIAN_524_20","journal-title":"Ann Indian Acad Neurol"},{"key":"503_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1294028","volume":"14","author":"J Cho","year":"2023","unstructured":"Cho J, Lee J, Kim J, Lee H, Kim MJ, Lee YJ, et al. Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea. Front Neurol. 2023;14:1294028 https:\/\/doi.org\/10.3389\/fneur.2023.1294028","journal-title":"Front Neurol"},{"key":"503_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dmcn.15171","volume":"64","author":"H Weststrate","year":"2022","unstructured":"Weststrate H, Stimpson G, Thomas L, Scoto M, Johnson E, Stewart A, et al. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2022;64:907\u201314. https:\/\/doi.org\/10.1111\/dmcn.15171","journal-title":"Dev Med Child Neurol"},{"key":"503_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-230162","volume":"11","author":"N Cornell","year":"2024","unstructured":"Cornell N, Childs AM, Wraige E, Munot P, Ambegaonkar G, Chow G, et al. Risdiplam in spinal muscular atrophy: safety profile and use through the early access to medicine scheme for the paediatric cohort in Great Britain. J Neuromuscul Dis. 2024;11:361\u20138. https:\/\/doi.org\/10.3233\/JND-230162","journal-title":"J Neuromuscul Dis"},{"key":"503_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2023.04.007","volume":"144","author":"I Tokatly Latzer","year":"2023","unstructured":"Tokatly Latzer I, Sagi L, Lavi R, Aharoni S, Bistritzer J, Noyman I, et al. Real-life outcome after gene replacement therapy for spinal muscular atrophy: a multicenter experience. Pediatr Neurol. 2023;144:60\u20138. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.04.007","journal-title":"Pediatr Neurol"},{"key":"503_CR54","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","volume":"28","author":"HG Ali","year":"2021","unstructured":"Ali HG, Ibrahim K, Elsaid MF, Mohamed RB, Abeidah MIA, Al Rawwas AO, et al. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther. 2021;28:676\u201380. https:\/\/doi.org\/10.1038\/s41434-021-00273-7","journal-title":"Gene Ther"},{"key":"503_CR55","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. 2019;266:2129\u201336. https:\/\/doi.org\/10.1007\/s00415-019-09389-8","journal-title":"J Neurol"},{"key":"503_CR56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","volume":"32","author":"A Tscherter","year":"2022","unstructured":"Tscherter A, R\u00fcsch CT, Baumann D, Enzmann C, Hasselmann O, Jacquier D, et al. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscul Disord. 2022;32:399\u2013409. https:\/\/doi.org\/10.1016\/j.nmd.2022.02.001","journal-title":"Neuromuscul Disord"},{"key":"503_CR57","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3390\/pharmaceutics14102074","volume":"14","author":"M Axente","year":"2022","unstructured":"Axente M, Mirea A, Sporea C, P\u0103dure L, Dr\u0103goi CM, Nicolae AC, et al. Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment. Pharmaceutics. 2022;14:2074 https:\/\/doi.org\/10.3390\/pharmaceutics14102074","journal-title":"Pharmaceutics"},{"key":"503_CR58","doi-asserted-by":"publisher","unstructured":"Mirea A, Leanca MC, Onose G, Sporea C, Padure L, Shelby ES.et al. Physical therapy and nusinersen impact on spinal muscular atrophy rehabilitative outcome. Front Biosci (Landmark Ed). 2022;27:179 https:\/\/doi.org\/10.31083\/j.fbl2706179","DOI":"10.31083\/j.fbl2706179"},{"key":"503_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15310","volume":"64","author":"Hepkaya","year":"2022","unstructured":"Hepkaya, K\u0131l\u0131n\u00e7 Sakall\u0131 E, \u00dclkersoy AA, \u0130, Ba\u015fkan AK, Arslan H, et al. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy. Pediatr Int. 2022;64:e15310 https:\/\/doi.org\/10.1111\/ped.15310","journal-title":"Pediatr Int"},{"key":"503_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15175","volume":"64","author":"AP Ergenekon","year":"2022","unstructured":"Ergenekon AP, Yilmaz Yegit C, Cenk M, Gokdemir Y, Erdem Eralp E, Ozturk G, et al. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen. Pediatr Int. 2022;64:e15175 https:\/\/doi.org\/10.1111\/ped.15175","journal-title":"Pediatr Int"},{"key":"503_CR61","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s10072-023-06698-9","volume":"44","author":"D Arslan","year":"2023","unstructured":"Arslan D, Inan B, Kilinc M, Bekircan-Kurt CE, Erdem-Ozdamar S, Tan E. Nusinersen for adults with spinal muscular atrophy. Neurol Sci. 2023;44:2393\u2013400. https:\/\/doi.org\/10.1007\/s10072-023-06698-9","journal-title":"Neurol Sci"},{"key":"503_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03063-3","volume":"23","author":"H Yang","year":"2023","unstructured":"Yang H, Tao Q, Li D, Yang J, Cai Q, Gan J, et al. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study. BMC Neurol. 2023;23:35 https:\/\/doi.org\/10.1186\/s12883-023-03063-3","journal-title":"BMC Neurol"},{"key":"503_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.17650\/2222-8721-2022-12-1-29-38","volume":"12","author":"SB Artemyeva","year":"2022","unstructured":"Artemyeva SB, Papina YO, Shidlovskaya OA, Monakhova AV, Vlodavets DV. Experience of using gene replacement therapy with Zolgensma\u00ae (onasemnogene abeparvovec) in real clinical practice in Russia. Neuromuscul Dis. 2022;12:29\u201338. https:\/\/doi.org\/10.17650\/2222-8721-2022-12-1-29-38.","journal-title":"Neuromuscul Dis"},{"key":"503_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","volume":"8","author":"R De Holanda Mendonca","year":"2021","unstructured":"De Holanda Mendonca R, Jorge Polido G, Ciro M, Jorge Fontoura Solla D, Conti Reed U, Zanoteli E. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen. J Neuromuscul Dis. 2021;8:217\u201324. https:\/\/doi.org\/10.3233\/JND-200533","journal-title":"J Neuromuscul Dis"},{"key":"503_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","volume":"30","author":"D Osredkar","year":"2021","unstructured":"Osredkar D, J\u00edlkov\u00e1 M, Butenko T, Loboda T, Golli T, Fuchsov\u00e1 P, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2020.11.004","journal-title":"Eur J Paediatr Neurol"},{"key":"503_CR66","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/jnnp-2020-324532","volume":"92","author":"SH Chan","year":"2021","unstructured":"Chan SH, Chae JH, Chien YH, Ko TS, Lee JH, Lee YJ, et al. Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions. J Neurol Neurosurg Psychiatry. 2021;92:1244\u20136. https:\/\/doi.org\/10.1136\/jnnp-2020-324532","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"503_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u00df","year":"2022","unstructured":"Wei\u00df C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6:17\u201327. https:\/\/doi.org\/10.1016\/S2352-4642(21)00287-X","journal-title":"Lancet Child Adolesc Health"},{"key":"503_CR68","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/dmcn.14412","volume":"62","author":"K Aragon-Gawinska","year":"2020","unstructured":"Aragon-Gawinska K, Daron A, Ulinici A, Vanden Brande L, Seferian A, Gidaro T, et al. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2020;62:310\u20134. https:\/\/doi.org\/10.1111\/dmcn.14412.","journal-title":"Dev Med Child Neurol"},{"key":"503_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R G\u00fcnther","year":"2024","unstructured":"G\u00fcnther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, et al. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg Health Eur. 2024;39:100862 https:\/\/doi.org\/10.1016\/j.lanepe.2024.100862","journal-title":"Lancet Reg Health Eur"},{"key":"503_CR70","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"T Friedmann","year":"1972","unstructured":"Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175:949\u201355. https:\/\/doi.org\/10.1126\/science.175.4025.949","journal-title":"Science"},{"key":"503_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","volume":"120","author":"SR Choudhury","year":"2017","unstructured":"Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. 2017;120:63\u201380. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.02.013","journal-title":"Neuropharmacology"},{"key":"503_CR72","unstructured":"Luxturna. (voretigene neparvovec-rzyl) intraocular suspension for subretinal injection Spark Therapeutics Available at: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee Accessed October 7, 2022."},{"key":"503_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1089\/hum.2020.159","volume":"32","author":"TI Cornu","year":"2021","unstructured":"Cornu TI, Mussolino C, Muller MC, Wehr C, Kern WV, Cathomen T. HIV gene therapy: an update. Hum Gene Ther. 2021;32:52\u201365. https:\/\/doi.org\/10.1089\/hum.2020.159","journal-title":"Hum Gene Ther"},{"key":"503_CR74","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1582-4934.2010.01038.x","volume":"14","author":"P Nilsson","year":"2010","unstructured":"Nilsson P, Iwata N, Muramatsu S, Tjernberg LO, Winblad B, Saido TC. Gene therapy in Alzheimer\u2019s disease - potential for disease modification. J Cell Mol Med. 2010;14:741\u201357. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01038.x","journal-title":"J Cell Mol Med"},{"key":"503_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","volume":"98","author":"LP Lowes","year":"2019","unstructured":"Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW, McColly M, et al. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39\u201345. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.05.005","journal-title":"Pediatr Neurol"},{"key":"#cr-split#-503_CR76.1","unstructured":"Novartis AG Zolgensma acute liver failure update [Internet]. c2024 [updated 2022 Aug 11"},{"key":"#cr-split#-503_CR76.2","unstructured":"cited 2024 Aug 10]. Available from: https:\/\/www.novartis.com\/news\/zolgensma-acute-liver-failure-update."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00503-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:16:01Z","timestamp":1753956961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00503-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00503-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3488410\/v1","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OS received research grant from Novartis and Thermo Fisher Scientific. OS received honoraria for lectures and Speaker\u2019s Bureau from F. Hoffmann\u2013La Roche and Novartis. OS serves as a board member of the Foundation to Eradicate Neuromuscular Diseases (FEND) and advisory panel for Thai SMA group.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This systematic review and meta-analysis does not require IRB approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}